BGI Genomics announced that its controlling shareholder, Shenzhen BGI Genomics Technology Company, released 7.6 million pledged shares and simultaneously pledged another 6.9 million shares. As of the disclosure date, the controlling shareholder has pledged a cumulative 90.73 million shares, accounting for 72.84% of its total holdings. In the first quarter of 2026, BGI Genomics achieved revenue of 809 million yuan and a net loss attributable to the parent company of 9.52 million yuan.
BGI Genomics Co LtdControlling shareholder pledged 72.84% of its stake, signaling financial strain and potential dilution risk.
